Compugen Ltd CGEN:NASDAQ

RT Quote | Last NYSE, VOL From CTA | USD
Last | 10:46 AM EDT
1.95quote price arrow up+0.02 (+1.04%)
Volume
340,589
52 week range
1.66 - 9.20
Loading...
  • Open1.87
  • Day High1.95
  • Day Low1.85
  • Prev Close1.93
  • 52 Week High9.20
  • 52 Week High Date06/28/21
  • 52 Week Low1.66
  • 52 Week Low Date05/11/22

Key Stats

  • Market Cap168.54M
  • Shares Out86.43M
  • 10 Day Average Volume1.19M
  • Dividend-
  • Dividend Yield-
  • Beta2.44
  • YTD % Change-55.35

KEY STATS

  • Open1.87
  • Day High1.95
  • Day Low1.85
  • Prev Close1.93
  • 52 Week High9.20
  • 52 Week High Date06/28/21
  • 52 Week Low1.66
  • 52 Week Low Date05/11/22
  • Market Cap168.54M
  • Shares Out86.43M
  • 10 Day Average Volume1.19M
  • Dividend-
  • Dividend Yield-
  • Beta2.44
  • YTD % Change-55.35

RATIOS/PROFITABILITY

  • EPS (TTM)-0.40
  • P/E (TTM)-4.87
  • Fwd P/E (NTM)-3.84
  • EBITDA (TTM)-34.806M
  • ROE (TTM)-32.54%
  • Revenue (TTM)6.00M
  • Gross Margin (TTM)88.67%
  • Net Margin (TTM)-566.80%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date07/26/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Compugen Ltd

There is no recent news for this security.

Profile

MORE
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs...
Paul Sekhri
Non-Executive Independent Chairman of the Board
Anat Cohen-Dayag Ph.D.
President, Chief Executive Officer, Director
Ari Krashin CPA
Chief Financial Officer, Chief Operating Officer
Address
Azrieli Center, 26 Harokmim St. Bldg D
Holon
5885849
Israel